Retatrutide: A Research Overview

Retatrutide (Eli Lilly's internal code LY3437943) is an investigational, injectable molecule designed to activate three separate hormone receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor [1][11]. It is being developed by Eli Lilly and Company and, as far as we could verify, has not been approved by any medicines regulator anywhere in the world as of this article's publication date [1][3].

Retatrutide's glucagon-receptor activity is what distinguishes it from earlier incretin-class drugs such as semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP). Glucagon signalling increases energy expenditure and promotes breakdown of stored liver fat, which researchers believe helps explain the unusually large weight reductions and liver-fat improvements reported in early trials [2]. That combination — reduced appetite, improved glucose and fat handling, and increased energy expenditure in a single weekly injection — is the scientific basis for the interest in this molecule, not a guarantee of any individual outcome.

Retatrutide combines three natural gut-hormone pathways in one molecule [1][6]:

• GLP-1 receptor activity — the same pathway targeted by semaglutide — slows stomach emptying, increases fullness, and helps regulate insulin release after eating.
• GIP receptor activity — partially shared with tirzepatide — is thought to improve fat-cell metabolism and insulin sensitivity alongside GLP-1 signalling.
• Glucagon receptor activity increases energy expenditure and promotes breakdown of stored liver fat, and is believed to drive retatrutide's comparatively large effect on liver fat specifically [2].

Phase 1 (protocol J1I-MC-GZBA, begun 2019) established a terminal half-life of roughly 5–7 days, supporting once-weekly dosing, and identified dose-dependent gastrointestinal effects and transient increases in heart rate with decreases in blood pressure.

Phase 2 (ClinicalTrials.gov NCT04881760 [3]) was a randomised, placebo-controlled trial in 338 adults, published in the New England Journal of Medicine in 2023 [2]. At the highest (12mg) dose tested, mean weight reduction reached roughly 17.5% at 24 weeks and 24.2% at 48 weeks, with weight still declining when treatment stopped — meaning the trial did not observe a plateau within its timeframe. A companion Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (MASLD/MASH) reported very large relative reductions in liver fat.

Phase 3 is organised as Lilly's TRIUMPH registrational program, spanning several large trials and nested sub-studies: TRIUMPH-1 (obesity/overweight, with nested studies in knee osteoarthritis and sleep apnea), TRIUMPH-2 (type 2 diabetes with obesity/overweight), TRIUMPH-3 (severe obesity with cardiovascular disease), TRIUMPH-4 (obesity with knee osteoarthritis), and TRIUMPH-Outcomes (a dedicated cardiovascular/kidney outcomes trial) [1][3][7]. Reported topline results (from company/trade-press disclosures, not yet full peer-reviewed papers) describe weight reductions of roughly 20–28% across these trials depending on population and duration. Further Phase 3 studies target type 2 diabetes with renal impairment, chronic kidney disease, and chronic low back pain.

Lilly has stated an intention to submit a Biologics License Application to the U.S. FDA in Q1 2027, after earlier signalling a possible 2026 submission — a company-stated intention, not a confirmed filing or approval date [1].

Beyond obesity and type 2 diabetes, indications under active Phase 3 investigation include cardiovascular risk reduction in people with obesity, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease/steatohepatitis, obstructive sleep apnea, knee osteoarthritis pain, and chronic low back pain [3][7]. None of these uses are approved anywhere; all remain investigational.

Peer-reviewed evidence (the 2023 NEJM Phase 2 paper) establishes meaningful weight and metabolic effects over 48 weeks in a controlled trial of 338 people [2]. It does not establish long-term safety beyond the trial period, real-world effectiveness outside a monitored trial, or that any commercially sold "research peptide" product is the same material tested. Phase 3 topline figures are currently sourced from company press disclosures rather than peer-reviewed publications, and should be read as preliminary pending full publication.

Across Phase 1 through Phase 3, the most consistently reported adverse events are gastrointestinal: nausea, vomiting, diarrhea, constipation and abdominal distension, generally dose-dependent and concentrated during dose escalation [2]. Phase 1 data also showed dose-dependent increases in heart rate and decreases in blood pressure that returned toward baseline by day 29. A newer signal reported in Lilly's TRIUMPH-4 topline results is dysesthesia (abnormal skin sensations such as tingling, burning or numbness) at meaningfully higher rates than placebo at higher doses; Lilly has characterised these as generally mild, but this finding has not yet appeared in a peer-reviewed paper and independent confirmation should be sought before treating exact incidence figures as settled. Discontinuation rates due to adverse events have been reported in trade press in the rough range of 6–16% among treated participants versus near-zero on placebo, though this figure is not yet independently confirmed against a peer-reviewed primary source.

Retatrutide has not been approved by the FDA, the EMA, or any other regulator we could identify, as of this article's publication date. The only sanctioned way to receive it currently is enrolment in one of Lilly's registered clinical trials [3]. Separately, Lilly and the FDA have an unresolved dispute over whether retatrutide should be classified and reviewed as a biologic (via a Biologics License Application) or as a small-molecule drug (via a New Drug Application) — a classification question that could affect submission timing, though it does not change retatrutide's current unapproved status either way.

SAHPRA (the South African Health Products Regulatory Authority) has published a general public warning about unregistered, compounded, substandard and falsified GLP-1 and GIP/GLP-1-class products sold online, on social media, and through informal channels in South Africa [4][5]. SAHPRA's position is that selling a registerable medicine that is not SAHPRA-registered is an offence under the Medicines and Related Substances Act, and that compounded products claiming GLP-1-class active ingredients have not been verified by SAHPRA for identity, purity or safety. As of the sources we reviewed, only liraglutide, semaglutide and tirzepatide are SAHPRA-approved injectable GLP-1-class medicines — retatrutide is not among them. South African news coverage in 2026 separately reported on a broader "shadow market" for retatrutide sold online and through gyms in South Africa [9][10]. We could not directly confirm SAHPRA's page text first-hand during this research (a technical access issue), so we describe SAHPRA's position only in the general terms supported by the sources we could verify, rather than quoting it verbatim.

It is worth being explicit about a distinction that vendor marketing routinely blurs: the weight-loss and safety figures reported above come from a controlled clinical trial using material manufactured, stored and dosed under Good Manufacturing Practice and direct regulatory oversight, in a monitored population, over a defined period. None of that chain of control applies automatically to a product bought from an online vendor. Citing a trial statistic on a product page — as some South African vendors do — provides context about the molecule; it is not evidence about the specific vial a buyer receives.

Vendors commonly label these products "research chemicals," "not for human consumption," or "for laboratory/research use only." This is a legal and marketing framing intended to position a sale outside medicines regulation — it is not a safety, purity, or quality designation. It does not mean a product has been verified for identity, purity, sterility or correct concentration, and it does not mean the product is equivalent to clinical-trial material. Regulators including SAHPRA have specifically flagged "research use only" labelling as a pattern used to market unapproved substances to consumers while attempting to sidestep medicines law [4][5]. Our vendor scoring methodology treats a "research use only" disclaimer as a transparency signal about how a vendor frames its sale — never as evidence that a specific product is safe, pure, or authentic.

Without an independently verified, viewable Certificate of Analysis tied to the specific batch sold — checked against the named laboratory's own records — there is no way for a buyer or a reviewer to confirm that a vendor's product matches its labelled identity, purity or concentration. Our vendor reviews record, vendor by vendor, which sellers publish this kind of checkable testing evidence and which do not, and are explicit about which claims we could and could not independently verify.

• Further Phase 3 (TRIUMPH) topline readouts, which Lilly and trade press have indicated were expected through the rest of 2026 — treat any specific date as approximate and company-guided, not confirmed.
• The unresolved Lilly–FDA dispute over biologic versus small-molecule classification, which could affect submission timing.
• Lilly's stated intention to submit a Biologics License Application to the FDA in Q1 2027.
• Full peer-reviewed publication of Phase 3 safety and efficacy data, including formal characterisation of the dysesthesia signal reported in topline disclosures.
• Any EMA or other non-U.S. regulatory developments, none of which had a concrete public timeline in the sources we reviewed.